Recent Updates
Recently added Catalysts
SNYR

EMBARGOED FOR USE BEFORE Contact: After 9am (Eastern) Jack Ross, Chairman / CEO

Key Takeaway: EMBARGOED FOR USE BEFORE Contact: After 9am (Eastern) Jack Ross, Chairman / CEO November 16, 2015 Synergy CHC Corp Jack@synergychc.com 615-939-9004 CHC Corp Acquires Another Quality Brand in "UrgentRx" Maine, November 16, 2015 - Synergy CHC Corp (OTCQB: SNYR) a consumer healt

Full Press Release Details

EMBARGOED FOR USE BEFORE Contact:
After 9am (Eastern) Jack Ross, Chairman / CEO
November 16, 2015 Synergy CHC Corp
Jack@synergychc.com
615-939-9004
CHC Corp Acquires Another Quality Brand in "UrgentRx"
Maine, November 16, 2015 - Synergy CHC Corp (OTCQB: SNYR) a consumer health care company, today announced it has
acquired a 100% ownership stake in Breakthough Products, Inc. (UrgentRx). UrgentRx is engaged in the business of developing and
selling medications for headache, heart burn, allergy attack, ache and pain, and upset stomach in the form of powders.
the terms of the agreement, Synergy purchased all the issued and outstanding capital stock of UrgentRx in exchange for 6,000,000
shares of Synergy common stock. In addition, Synergy agreed to pay a royalty to a trust for the benefit of the UrgentRx shareholders
equal to 5% of gross sales of the UrgentRx products following the first $5,000,000 in gross sales on a quarterly basis for a period
of seven years from the closing date.
believe UrgentRx will continue to thrive as it joins Synergy's expanding product portfolio while leveraging the momentum
of the platform and multiple economies of scale it provides," said Jordan
Eisenberg, CEO of UrgentRx. "This is a tremendous opportunity for UrgentRx to continue
to be consumers' best choice for fast, convenient relief. I am thrilled to join Jack Ross and the Synergy Management Team.
I believe we have a real opportunity to build a world-class consumer healthcare business bolstered by the most exciting and innovative
brands in the industry."
are pleased to add another unique offering to our portfolio; it is consistent with the company's strategy to grow by further
acquisition. We are deliberately seeking to generate shareholder value through the addition of products that help improve the
lives of customers while leveraging our existing distribution relationships. We will continue to be active on the acquisition
trail," said Jack Ross, President and CEO of Synergy.
produces a line of fast-acting, portable OTC medications that provide right now relief for today's busy, on-the-go
consumer. UrgentRx Fast Powders are innovative, fast-acting flavored powder medications in patented credit card-sized
packets. They can be taken without water, providing immediate relief for a wide variety of everyday ailments, whenever and
wherever they strike. UrgentRx produces medications to treat allergy attacks, headaches, aches and pains, heartburn, and
upset stomach, as well as a heart attack first aid that has helped save multiple lives.
is successfully disrupting and bringing much-needed innovation to the OTC category by offering products that fit contemporary
consumers' lifestyles. Answering these consumers' unmet needs, UrgentRx is rapidly becoming the "go-to"
brand for on-the-go relief. The line is sold in over 35,000 stores nationwide, including many leading national food, drug, mass,
convenience and travel retailers. Notably, UrgentRx pioneered the use of "found space" displays that take advantage
of previously-unutilized space at checkout.
company was orginally funded by Sam Zell, David Bonderman, Herb Simon, Academy Award-winning actress Hilary Swank, worldwide
talent agency WME, as well as multiple family offices. UrgentRx has been featured on national talkshows The Doctors,
Ellen and The View and has received coverage in The New York Times, Entrepreneur, Fortune, CNN, The Wall
Street Journal, CNBC and Forbes. In 2015, UrgentRx won the prestigious Inc 5000 and was ranked as the 168th
fastest-growing company in America.
in Denver, Colorado, UrgentRx was founded by two-time Goldman Sachs "Most Intriguing Entrepreneur" Jordan Eisenberg.
Capital Securities, LLC was the investment bank for UrgentRx and its shareholders in this transaction. Joel Montminy, President
& CEO of CREO said "The Synergy team adeptly analyzed and efficiently closed on this highly complementary combination.
Under their watch, we believe UrgentRX will achieve exciting performance in the years ahead."
CHC Corp. is a consumer health care company that is in the process of building a portfolio of best-in-class consumer product brands.
Synergy's strategy is to grow its portfolio both organically and by further acquisition. Synergy's diversified portfolio
now includes FOCUSFactor , Neuragen , Hand MD , and UrgentRx .
For more information, please visit www.synergychc.com.
FOCUSfactor "Another Synergy Brand"
is sold at America's leading retailers such as Costco, Sam's Club, Wal-Mart, BJ's Walgreens and The Vitamin
Shoppe. FOCUSfactor, America's leading brain health supplement, is a nutritional supplement that includes a proprietary
blend of brain supporting vitamins, minerals, antioxidants and other nutrients. In December 2012, the United States Patent and
Trademark Office issued US Patent 8,329,227 covering FOCUSfactor's proprietary formulation "for enhanced mental function."
The issuance of the patent marked one of the few times a patent has been issued for a nationally branded nutritional supplement.
FOCUSfactor is clinically tested with results demonstrating improvements in focus, concentration and memory in healthy adults.
Neuragen "Another Synergy Brand"
is a topical product that works directly at the site of the pain as opposed to oral products. Neuragen reduces the spontaneous
firing of damaged peripheral nerves. By calming these firings at the source, Neuragen is clinically shown to reduce shooting
and burning pains quickly and without the side effects of orally taken medications. This is in part due to the small lipophilic
molecules found in Neuragen which rapidly carry the active ingredients through the rough outer layer of the skin to the site
of the pain. Neuragen is available over the counter in most local pharmacies either in the diabetic section or the analgesic
(pain) section. For more information, please visit www.neuragen.com.
Hand MD "Another Synergy Brand'
MD is the world's first anti-aging skincare line formulated specifically for the hands. Hands reveal a woman's true
age and the rejuvenation of the hand has become women's #1 aging concern. Developed by Kara Harshbarger and renowned celebrity
dermatologist Dr. Alex Khadavi, Hand MD's extensive clinical trials show significant improvement in the appearance of fine
lines and wrinkles, skin hydration, hyper-pigmentation and radiance. HAND MD launched on QVC and sold out in an astonishing 5
minutes. www.hand-md.com.
press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that
are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations,
beliefs, goals, plans or Synergy's prospects should be considered forward-looking. Readers are cautioned that actual results
may differ materially from projections or estimates due to a variety of important factors, including: Synergy's ability
to integrate the Urgent Rx and other recently acquired product lines into its current operations; Synergy's dependence
on third parties for its research and development, manufacturing and distribution functions; Synergy's' dependence
on its license relationships; the risks and uncertainties associated with Synergy's ability to manage its limited cash resources;
obtaining additional financing to support Synergy's operations; protecting the intellectual property developed by or licensed
to Synergy; and Synergy's ability to build its operations to support its business strategy and promote its products. These
and other risks are described in greater detail in Synergy's filings with the SEC, copies of which are available free of
charge at the SEC's website (www.sec.gov) or upon request from Synergy. Synergy may not actually achieve the goals or plans
described in its forward-looking statements, and investors should not place undue reliance on these statements. Synergy assumes
no obligation and does not intend to update these forward-looking statements, except as required by law.
Last updated: Nov 16, 2015